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Abstract
Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples
obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification)
summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and
evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among
patients within the same stage. The current classification provides limited prognostic information, and does not
predict response to therapy. Recent literature has alluded to the importance of the host immune system in
controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers,
implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from
large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic
value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to
incorporate the ‘Immunoscore’ into traditional classification, thus providing an essential prognostic and potentially
predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and
prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient
treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol
variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and
variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In
an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This
review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January
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2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this
international validation may result in the implementation of the Immunoscore as a new component for the
classification of cancer, designated TNM-I (TNM-Immune).
Background
Conventional clinical and pathological risk prediction in
cancer patients is usually achieved by histopathological
evaluation of tissue samples obtained during surgical re-
moval of the primary tumor. The histopathological char-
acteristics used can include: the size of the tumor; tissue
integrity; atypical cell morphology; histological grade; ab-
errant expression of protein and genetic markers; evi-
dence of malignant transformation, senescence and
proliferation; characteristics of the invasive margin (IM);
depth of invasion; and the extent of vascularization. In
addition, histological or radiological analyzes of tumor-
draining and regional lymph nodes, as well as of distant
organs, are carried out looking to identify evidence of
metastases. In accordance with this classification system,
the evaluation of cancer progression is performed longi-
tudinally and then applied to estimate patient prognosis.
The parameters used to predict disease-free (DFS),
disease-specific (DSS) and overall (OS) survival are taken
from statistical analysis of patients with similar disease
progression characteristics and corresponding clinical
outcome. Tumor staging (AJCC/UICC-TNM classifica-
tion) summarizes data on the extent of the tumor bur-
den (T), presence of cancer cells in draining and
regional lymph nodes (N) and evidence of metastases
(M). This classification, based only on tumor invasion
parameters, has been shown to be valuable in estimating
the outcome of patients with a variety of cancers [1-3].
However, these traditional classification tools provide
limited information in estimating patient post-operative
outcome. It is well known that clinical outcome can sig-
nificantly vary among patients within the same histo-
logical tumor stage [4]. In some patients, advanced stage
cancer can remain stable for years, and although rare,
partial or full regression of metastatic tumors can occur
spontaneously [5]. In contrast, relapse, rapid tumor pro-
gression and patient death is associated with approxi-
mately 20-25% of TNM I/II stage patients, despite
complete surgical resection and no evidence of residual
tumor burden or distant metastasis [5].
The predictive accuracy of this traditional staging sys-
tem relies on the assumption that tumor progression is
largely a cell-autonomous process. The focus of this
classification is solely on the tumor cells and fails to
consider and incorporate the effects of the host immune
response [6]. Histopathological analysis of tumors has
revealed the infiltration of inflammatory and lympho-
cytic cells [7]. Detailed intra-tumor analysis illustrates
that these immune infiltrates are not randomly distribu-
ted. Tumor-infiltrating immune cells appear to be loca-
lized and organized within dense infiltrates in the center
of the tumor (CT), at the IM of tumoral nests and in ad-
jacent tertiary lymphoid structures (TLS). The presence
of immune cells may reflect a distinct underlying biology
of the tumor, as gene expression profiling and other
assays have revealed the presence of a broad signature of
inflammation. This signature includes evidence for in-
nate immune activation, chemokines for innate and
adaptive cell recruitment, immune effector molecules,
and expression of immunoregulatory factors [8-10]. Im-
mune infiltrates are heterogeneous between tumor types,
and are diverse from patient to patient. All immune cell
types may be found in a tumor, including macrophages,
dendritic cells (DC), mast cells, natural killer (NK) cells,
naïve and memory lymphocytes, B cells and T lympho-
cytes (which include various subsets of T cell: TH1, TH2,
TH17, regulatory T cells (TREGS), T follicular helper cells
(TFH) and cytotoxic T cells). The analysis of the location,
density and functional orientation of different immune
cell populations (termed the immune contexture [11,12])
in large collections of annotated human tumors has
allowed the identification of components that are benefi-
cial for patients and those that are deleterious [6,9,12-14].
Nonetheless, to implement any new tumor biomarker in-
cluding immune infiltrates for routine clinical use, careful
evaluation of its laboratory validity and clinical utility is
essential [15].
Since tumor molecular features and immune reactions
are inter-related, a comprehensive assessment of these
factors is critical [16]. Examining the effects of tumor-
host interactions on clinical outcome and prognosis
clearly represents an evolving interdisciplinary field of
molecular pathological epidemiology, the paradigm of
which has recently been established [6,11,17,18]. Patho-
logical immunity evaluation may provide novel informa-
tion on prognosis and help identify patient cohorts more
likely to benefit from immunotherapy.
A new classification of cancer based on the tumor
microenvironment
Increasing literature [9,11,13,14,19] and meeting reports
[20-22] support the hypothesis that cancer development
is influenced by the host immune system. A common
theme has emerged, emphasizing the critical need to
evaluate systemic and local immunological biomarkers.
It is in agreement that this may offer powerful
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prognostic information and facilitate clinical decision-
making regarding the need for systemic therapy [6,23].
Numerous data collected from large cohorts of human
cancers (with sample sizes n = 415, 599 and 602,
[9,13,14], respectively) demonstrated that the number,
type and location of tumor immune infiltrates in primary
tumors, are prognostic for DFS and OS. Altogether these
immune parameters are designated as the immune con-
texture [11,12]. Notably, two large studies (with sample
sizes n = 843 and 768, [24,25], respectively) have shown
that tumor immune infiltrate patterns and subsets in
colorectal cancer are significant prognostic biomarkers,
even after adjusting for stage, lymph node count, and
well-established prognostic tumor molecular biomarkers
including microsatellite instability (MSI), BRAF muta-
tion, and LINE- hypomethylation.
A potential clinical translation of these observations is
the establishment of an Immunoscore, based on the nu-
meration of two lymphocyte populations (CD3/CD45RO,
CD3/CD8 or CD8/CD45RO), both in the CT and in the
IM of tumors, as a clinically useful prognostic marker
[14]. For instance, colorectal cancer (CRC) patients with
local tumor, no detectable lymph node or distant metasta-
sis are usually treated by surgery alone. However, 20-25%
of these patients will have recurrence of their disease indi-
cating that occult metastases were already present at the
time of curative surgery. No tumor-associated marker pre-
dicts recurrence in these patients. The Immunoscore (“I”)
utilizes the numeration of CD8 and CD45RO cells in the
CT and the IM of resected tumors to provide a score ran-
ging from Immunoscore 0 (“I”0), when low densities of
both cell types are found in both regions, to Immunoscore
4 (“I”4), when high densities are found in both regions.
This Immunoscore approach was applied to 2 large in-
dependent cohorts (n = 602). Only 4.8% of patients
with a high “I”4, relapsed after 5 years and 86.2% were
alive. In comparison, 72% of patients with a low score
(“I”0 and “I”1) experience tumor recurrence and only
27.5% were alive at five years. These “I”0 and “I”1
patients potentially could have benefited from adjuvant
therapy, had the Immunoscore been incorporated into
the tumor staging [14].
The Immunoscore classification, demonstrating the
prevalence of immune infiltrates, potentially has a prog-
nostic significance superior to that of the AJCC/UICC
TNM-classification system. For all patients with CRC
stages I/II/III, multivariate Cox analysis revealed that the
immune criteria remained highly significantly associated
with prognosis. In contrast, the histopathologic staging
system (T stage, N stage, and tumor differentiation) was
no longer significant [13]. Tumor invasion was shown to
be statistically dependent on the nature of the host-
immune reaction. Indeed, the immune pattern remained
the only significant criteria over the classical AJCC/
UICC TNM-classification for DFS and OS, and led to an
editorial entitled “TNM staging in colorectal cancer: T is
for T cell and M is for memory” accompanying the pub-
lication by Mlecnik and Broussard et al. in the Journal of
Clinical Oncology [13,26]. It has thus been suggested
that the prevalence of post-surgical immune infiltrates,
and not tumor status, is the key indicator for reoccur-
rence, metastasis and therefore clinical outcome.
These results suggest that once human cancer be-
comes clinically detectable, the adaptive immune re-
sponse may play a critical role in preventing tumor
recurrence. The ability of effector-memory T cells to re-
call previously encountered antigens leads to a protect-
ive response. Following primary exposure to antigen,
memory T cells disseminate and are maintained for long
periods of time [27]. The trafficking properties and the
long-lasting antitumor capacity of memory T cells could
result in long-term immunity in human cancer.
Although first described in CRC, the impact of the im-
mune cytotoxic and memory T cell phenotype has been
demonstrated in many other human tumors and appears
to be a general phenomenon [23,28]. It is interesting to
note that the implications of this immune phenotype
apply not only to various organs of cancer origin (such
as breast, colon, lung, head and neck, kidney, bladder,
ovary, prostate), but also to various cancer cell types
(adenocarcinoma, squamous cell carcinoma, large cell
cancer, melanoma, etc).
A recent Nature Cancer Review meta-analysis [12]
summarizes the impact of immune cells including B
cells, NK cells, myeloid derived suppressor clls
MDSC, macrophages, and all subsets of T cells on
clinical outcome from more than 120 published arti-
cles. Beyond colorectal cancer, a strong T cell infiltra-
tion associated with good clinical outcome has been
reported in many different tumours, including melan-
oma, head and neck, breast, bladder, urothelial, ovar-
ian, esophageal, renal, prostatic, pancreatic, cervical,
medulloblastoma, merkel cell carcinoma, hepatocellu-
lar, gastric, and lung cancers [12]. Thus, high densities
of T cells (CD3+), of cytotoxic T cells (CD8+), and of
memory T cells (CD45RO+) were clearly associated
with a longer DFS (after surgical resection of the pri-
mary tumour) and/or OS.
The prognostic impact of other immune cells such as
B cells, NK cells, MDSC, macrophages, and subset of T-
helper populations, (TH2, TH17, TREG cells) may differ
depending on the type of cancer, and on the cancer stage
[12]. In contrast, T cells, cytotoxic T cells, TH1 cells, and
memory T cells were strongly associated with good clin-
ical outcome for all cancer types [12]. Thus, general
characteristics emerge in which cytotoxic T cells, mem-
ory T cells, and TH1 cells are associated with prolonged
survival.
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The Immunoscore as a new approach for the
classification of cancer
Considering the important role of the host immune signa-
ture in controlling tumor progression, it is now imperative
to initiate the incorporation of the Immunoscore as a
component of cancer classification [13,14] and a prognos-
tic tool [23]. This strategy has a dual advantage: firstly, it
appears to be the strongest prognostic factor for DFS and
OS, particularly in early stage cancers and secondly, it
could allude to potential targets for novel therapeutic
approaches, including immunotherapy. Current immuno-
histochemical technologies allow the application of such
analyses by laboratories concerned with routine diagnostic
and prognostic assessment of tumors.
The inherent complexity of immunohistochemistry, in
conjunction with protocol variability, analysis of differ-
ent immune cell types, inconsistent tissue region selec-
tion criteria, combined with differences in conjunction
with qualitative and semi-quantitative criteria to meas-
ure immune infiltration, all contribute to the variability
of the results obtained, and raise the concern that spe-
cialized protocols and training may be required. It is
therefore essential to pursue assay uniformity to reduce
these limitations. Many markers, signatures, and meth-
ods have been described to evaluate the prognosis of
cancer patients. Yet, very few such markers and labora-
tory assays are used in clinical practice. Thus, we believe
that harmonization of an assay evaluating the “inflam-
mation”, i.e. the Immunoscore of the tumor is essential.
Analytical and clinical validation of the assay is required
before the Immunoscore will reach clinical applicability
for individual patients. However, current immunohisto-
chemical technologies allow the application and cross-
validation of such analysis in laboratories performing
routine diagnostic and prognostic assessment of tumors.
In order to be able to compare results in the future, and
for the development of more effective prognostic and
predictive markers to improve clinical decision-making,
it is important to perform a standardized set of experi-
ments. Assay harmonization should minimize data vari-
ability and allow worldwide correlations of Immunoscore
results with clinical outcomes. Harmonization guidelines
resulting from this process are expected to be simple to
implement and will improve assay performance. Effective
large-scale assay harmonization efforts have already been
conducted for commonly used immunological assays of
peripheral blood immune cell populations [29,30].
A fundamental parameter to determine the Immuno-
score will include the immune cell density, calculated by
numerical quantification of two lymphocyte populations,
cytotoxic and memory T cells at the CT and the IM of
tumors. This core criterion will establish prognosis of
patient clinical outcome, regardless of the absence of
other cancer associated prognostic markers, such as in
early tumor stage (I/II) patients [14]. In human cancers,
a high density of TH1/cytotoxic memory T lymphocytes,
located both in the CT and IM of the primary tumor, is
associated with long DFS and OS, in addition to low risk
of relapse and metastasis. This was particularly illu-
strated in CRC [5,9,13,14,19], and should be applicable
to most human tumors [23]. Thus, this Immunoscore
classification may help identify the high-risk patients
who would benefit the most from adjuvant therapy.
Impact on response to cancer therapies
Whether the immune contexture of the primary tumor
predicts therapeutic responses is of paramount import-
ance for patient clinical management. Data based on im-
mune signatures have established that a strong immune
component is predictive of good response to chemother-
apy in breast cancer [31-33], a tumor in which a high
lymphocyte infiltrate is associated with higher response
rate in neo-adjuvant therapy [34,35]. In hepatic metastases
of CRC, high CD8 infiltrates in the IM predicts better re-
sponse to chemotherapy and prolonged survival [36]. In
melanoma, an immune signature displaying high expres-
sion of TH1 and cytotoxicity-associated genes, correlates
with favorable clinical outcome to several different thera-
peutic vaccines [8]. In addition, high numbers of CD8 T
cell infiltrates within metastatic melanoma correlated with
prolonged survival [37]. However, the high TH1 and cyto-
toxic immune response associated with prolonged survival
in patients receiving adjuvant therapies may not be a pre-
diction of response to the therapy, but rather the fact that
the host-immune response within the tumor protects the
patient and prolongs patient life. To assess the impact of
the Immunoscore as a predictive marker, it should be
evaluated prospectively in randomized clinical trials.
An open access call for a broad participation to the
development of a task force dedicated to the evaluation
of the Immunoscore in cancer patients
Over the past few years, the area of immune regulation at
the level of the tumor microenvironment has gained a
forefront position in cancer research, in CRC [9,12-14], in
melanoma [38] and all other cancer types [6]. The Immu-
noscore was initially described several years ago [9], and
more recently advances have been made in the develop-
ment of the Immunoscore as a prognostic factor [13,14]
that could be used in routine testing [39]. In an effort to
promote the utilization of such Immunoscore in routine
clinical settings worldwide, the Society for Immunother-
apy of Cancer (SITC), the European Academy of Tumor
Immunology (EATI), and “La Fondazione Melanoma
Onlus”, initiated a task force on “Immunoscoring as a
New Possible Approach for the Classification of Cancer”
that took place in Naples, Italy, February 13th, 2012 [39].
This perspective represents a follow-up on this initiative,
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originally announced in a J Transl Med. editorial in Janu-
ary 2012 [39]. The working group, composed of inter-
national expert pathologists and immunologists, identified
a strategy for the organization of worldwide participation
by various groups for the validation of the Immunoscore.
The objectives of the meeting included discussing: the role
of immune system in cancer; a review of the AJCC/UICC-
TNM classification of CRC; the role of the microenviron-
ment in melanoma biology; the review of the AJCC
classification of melanoma; the relevance of HLA-A2 in
cancer prognosis and tumor malignancy; data utilizing the
Immunoscore and a proposal for standardizing the operat-
ing procedures for the Immunoscore quantification. Fur-
thermore, the international working group evaluated the
feasibility of using the Immunoscore for the classification
of cancer. Evidence-based selection of specific markers
and their combinations for the Immunoscore was dis-
cussed including biological rationale, clinical use, synthetic
meta-analysis of the Immunoscore, analytical perform-
ance, reagents availability and testing, metrics for decision
making, cross-laboratory validation of methodology and
identification of potential problems during development
of other markers. Practical aspects of the validation of the
assay by participating centers were proposed including
consideration of cancer types, cancer stages, and the def-
inition of a working group of pathologists for the valid-
ation phase.
CRC has been most comprehensively studied and the
prognostic significance of immunologic parameters has
been best validated, thus special emphasis will be placed in
this disease for this formal validation. As neo-adjuvant
treatments are nowadays recommended for rectal cancer, it
may be advisable to separate the validation of colon cancers
and rectal cancers. Other cancer types, including melanoma
and breast cancers were additionally discussed and their
validation will follow. An independent international con-
sensus panel of expert laboratories discussed cross-
laboratory assay validation for the development of an
Immunoscore prognostic method. As evaluation of cyto-
toxic memory CD8+ Tcells (CD3+, CD8+, CD45RO+, Gran-
zyme B+ (GZMB)) provides the best method to
discriminate patient outcome, any combination of two of
these aforementioned markers should have similar statis-
tical power. Because of technical difficulties including back-
ground noise (CD45RO) and granular staining (GZMB), it
was decided to employ the two easiest membrane stains,
CD3 and CD8. Thus, the combination of two markers
(CD3+ and CD8+) in two regions (CT and IM) was agreed
for validation in standard clinical practice. Precise quantifi-
cation will be performed on whole slide sections (Figure 1).
For harmonization of the assay and reproducibility of the
method, all laboratories agreed to test the prognostic value
of specific immune cell infiltration following the recom-
mended initial guidelines. The inherent complexity of
quantitative immunohistochemistry underscored the urgent
need to reach assay harmonization. The components of the
Immunoscore are listed in Table 1. Additional markers
could be added subsequently to refine the methodology
even further if required. After worldwide validation, a con-
sensus detailed protocol will be available.
To be used globally in a routine manner, evaluation of
a novel marker should have the following characteristics:
pathology-based, feasible in routine settings, simple, in-
expensive, rapid, robust, reproducible, quantitative, stan-
dardized, and powerful. The Immunoscore fulfills all
these keys aspects summarized in Table 2.
The purpose of the Immunoscore worldwide task force
is to validate these points.
The goals of the first ongoing initiative are the
following:
1) to demonstrate the feasibility and reproducibility of
the Immunoscore.
2) to validate the major prognostic power of the
Immunoscore in routine settings for patients with
colon cancer stage I/II/III.
3) to demonstrate the utility of the Immunoscore to
predict stage II colon cancer patients with high risk
of recurrence.
Thus, the benefit of the Immunoscore worldwide
study would be to validate the feasibility, reproducibility,
CD3 
CD8 
Immunoscore (CT+IM)  
Hi 
Hi Hi 
Hi Hi Hi 
Hi Hi Hi Hi 
CT
IM
Tumor regions (CT & IM)  Immunostainings  
Digital Pathology 
Figure 1 Immunoscore definition and method.
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and prognostic value of the routine Immunoscore on
colon cancer patients.
The goals of the next initiatives will be the following:
1) promote the worldwide use of the Immunoscore as a
routine testing for cancer classification.
2) to validate the major prognostic power of the
Immunoscore for patients with other cancer types
(melanoma, breast, ovarian, endometrial, etc. . .).
3) to demonstrate the utility of the Immunoscore to
predict response to treatments in clinical trials.
In the inaugural World Immunotherapy Council meet-
ing (February 21st - 24th 2012, Curacao), the Immunoscore
task force, led by the Society for Immunotherapy of
Cancer (SITC), received the support from several add-
itional cancer immunology societies including; Biotherapy
Development Association (BDA); Canadian Cancer Im-
munotherapy Consortium (CCIC); Cancer Immunother-
apy Consortium (CIC) of the Cancer Research Institute
(CRI); Association for Cancer Immunotherapy (CIMT);
Committee for Tumor Immunology and Bio-therapy
(TIBT); European Academy of Tumor Immunology
(EATI); European Society for Cancer Immunology and
Immunotherapy (ESCII); Italian Network for Tumor
Biotherapy (NIBIT); Japanese Association of Cancer Im-
munology (JACI); Nordic Center for Development of
Antitumor Vaccines (NCV-network); Progress in Vaccin-
ation Against Cancer (PIVAC); Adoptive engineered T cell
Targeting to Activate Cancer Killing (ATTACK) and the
Tumor Vaccine and Cell Therapy Working Group
(TVACT). These groups share a clinical or basic interest
in the immunobiology of the tumor microenvironment
and will collaborate with worldwide expert pathologists to
assess the validity of this new approach. Following the
Immunoscore Workshop and the World Immunotherapy
Council meeting, 22 international expert centers agreed to
participate in this visionary enterprise. These participants
represent 22 Centers Worldwide from 16 countries in-
cluding Asia, India, Europe, North America, Australia,
and Middle East (Figure 2). Additionally, pathologist asso-
ciations and other medical specialty groups have been
invited to participate.
A preliminary summary of this effort will be pre-
sented during the “Workshop on Tumor Microenvir-
onment” prior to the SITC annual meeting (October
24th - 25th 2012, Maryland, USA). Finally a “Work-
shop on Immunoscore” (December 5th 2012, Naples,
Italy), will lead to the preparation of a summary
document providing recommendations for the har-
monization and implementation of the Immunoscore
as a new component for the classification of cancer
TNM-I (Immune).
Table 1 Current Immunoscore procedure and reagents
Procedure Current recommended steps
Tumor selection Block which is the most infiltrated by the immune
cells and containing the core of the tumor (CT)
and the invasive margin (IM)
Sample preparation 2 paraffin sections of 4-microns of the tumor
block deposited in deionized water on Superfrost-
plus slides
Immuno-
histochemistry (IHC)
2 single stainings using IVD certified antibodies
Antigen retrieval CC1 tris-based buffer pH8
Primary antibody CD3 (2GV6, Ventana) and CD8 (C8/144, Dako)
Primary antibody
diluant
K 004 (Clinisciences) for CD8
Secondary reagents Ultraview TM DAB (Ventana)
Counterstaining Hematoxillin II (Ventana)
Autostrainer Benchmark XT (Ventana)
Scanner NanoZoomer 2.0-HT (Hammamatsu)
Digital pathology Architect XD software (Definiens)
Immunoscore
quantification
Immunoscore Plug-in (INSERM / AP-HP)
Table 2 Characteristics of a good marker and of the Immunoscore
Must be Immunoscore Characteristics
Routine YES Technic to be performed by pathologist using bright field and precise cell evaluation
Feasible YES Established pathology technics, using 2 regular whole slide FFPE section
Inexpensive YES Automatized immunohistochemistry
Rapid YES 2 simple staining less costly than complicated molecular techniccs
Robust YES Autostainers, scanner, and digital pathology reduce the time to perform an Immunoscore
Reproducible YES Two strong membrane staining, with no background, allowing the numeration of individual cells
Quantitative YES Inter-observers variability is removed by the use of digital pathology, taking into account cell location and counts
Standardized YES Standardized operating procedure should be performed to insure reproducibility and worldwide comparisons
Pathology-base YES Necessity of pathologist expertise to validate cell type, cell location, and cell counts performed by digital pathology
Powerful YES The immunoscore has a prognostic value highly significant even in Cox multivariate including TNM classification13
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Conclusion
Prediction of clinical outcome in cancer is usually
achieved by histopathological evaluation (AJCC/UICC-
TNM classification) of tissue samples obtained during
surgical resection of the primary tumor. However, it is
now recognized that clinical outcome can significantly
vary among patients within the same stage. The current
classification provides limited prognostic information,
and does not predict response to therapy. Recent litera-
ture demonstrated the importance of the host immune
system in controlling tumor progression. Accumulating
data, collected from large cohorts of human cancers, has
demonstrated the impact of immune-classification,
which has a prognostic value that may add to the signifi-
cance of the current classification, and that has been
demonstrated to be superior to the AJCC/UICC TNM-
classification in colorectal cancer. It is therefore impera-
tive to begin to incorporate the ‘Immunoscore’ into trad-
itional classification, thus providing an essential
prognostic and potentially predictive tool. Given the
power of a proper immune evaluation of cancer patients,
the Immunoscore is likely to be important for the field
of cancer, beyond the field of tumor-immunology. In an
effort to promote the Immunoscore in routine clinical
settings, an international task force was initiated. The
results of this international validation may result in the
implementation of the Immunoscore as a new compo-
nent for the classification of cancer, designated TNM-I
(TNM-Immune). It is hoped that this effort will better
define the prognosis of cancer patients, better identify
patients at high-risk of tumor recurrence, to improve
the quality of life by predicting and stratifying patients
who will benefit from adjuvant therapies and, ultimately,
to help save the lives of patients with cancer.
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